Dwarka, New Delhi-110077, India
+1(919)321-6187

ESMO and ASCO Abstracts 2020

ASCO and ESMO Abstracts

ESMO Abstracts:

CheckMate 067 Results at ESMO 2020

Abstract No : Abstract: #1105P

Indication : Melanoma

Intervention : Nivolumab

Company : Bristol-Myers Squibb

Technology : PD-1/PD-L1 inhibitor

Mixture models adequately captured the survival plateaus in CheckMate 067 and suggested a higher proportion of LTSs with NIVO and NIVO+IPI than with IPI. These methods may be used in the indirect estimation of auxiliary outcomes, such as time to subsequent treatment and impact of subsequent treatments on LTSs.

Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-067-NCT01844505-esmo-2020

 

CheckMate -577 Results at ESMO 2020

Abstract No : Abstract: #LBA9

Indication : Esophageal Cancer, Gastroesophageal junction cancer

Intervention : Nivolumab

Company : Bristol-Myers Squibb

Technology : PD-1/PD-L1 inhibitor

Adjuvant nivolumab is the first therapeutic to provide a statistically significant and clinically meaningful improvement in DFS vs placebo and a well-tolerated safety profile in patients with resected EC/GEJC, who have received neoadjuvant CRT. These results represent the first treatment advance in many years for these patients, potentially establishing adjuvant nivolumab as a new standard of care.

Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-577-esmo-2020

 

KEYNOTE-590 Results at ESMO 2020

Abstract No : Abstract #LBA8

Indication : Esophageal cancer

Intervention : Pembrolizumab

Company : Merck & Co.

Technology : PD-1/PD-L1 inhibitor

Pembro + chemo provided superior OS, PFS, and ORR vs chemo, with a manageable safety profile in pts with untreated, advanced esophageal and EGJ cancer. These data demonstrate that 1L pembro + chemo is a new standard of care in this pt population.

Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-590-NCT03189719-esmo-2020

 

ASCO Abstracts:

ASCO: Results of KEYNOTE-426

Abstract No : 5001

Abstract Type : Oral Abstract Session

Indication : Renal Cell Carcinoma

Intervention : Pembrolizumab + axitinib

Company : Merck & Co.

Technology : Immune Checkpoint Inhibitor (ICI)

Pembro + axi continued to demonstrate superior and durable antitumor activity vs sunitinib in pts with first-line aRCC with a 27-mo median follow up; no new safety signals were observed.

Read More: https://www.delveinsight.com/asco-conference/article/NCT02853331

 

Leave a comment